Markets

Insider Trading

Hedge Funds

Retirement

Opinion

17 Deadliest And Most Common Cancers In The World

In this article, we will be taking a look at the 17 deadliest and most common cancers in the world. If you do not want to read about the global cancer statistics, head straight to the 5 Deadliest And Most Common Cancers In The World

Overview of Common Cancers: Understanding the prevalent types affecting populations globally. 

The prevalence of cancer varies across different types and populations, and the impact extends beyond the realms of health, seeping into economic domains. According to the Annual Report to the Nation 2022, childhood cancers, including leukemia, brain and other nervous system, and lymphoma, have seen increasing incidence trends from 2001-2018. In the broader context of the Global Economic Cost of 29 Cancers study, the five cancers with the highest economic costs are tracheal, bronchus, and lung cancer (15.4%); colon and rectum cancer (10.9%); breast cancer (9.6%); liver cancer (9.5%); and stomach cancer (7.6%). 

The economic consequences of a cancer diagnosis are profound, as highlighted by the substantial financial statistics associated with cancer care. The National costs for cancer care were estimated to be $190.2 billion in 2015, with costs soaring to $208.9 billion in 2020. A closer look at the American Cancer Society’s most recent data for 2022 reveals an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States alone. 

This economic burden is not just a statistical figure; it translates into tangible financial challenges for individuals. A study found that breast cancer survivors experienced a 21% loss of mean income within one year of diagnosis.  

Global Cancer Statistics and Impact

The global cancer statistics for 2020 paint a stark picture, revealing an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths worldwide. The most frequently diagnosed cancers include female breast, lung, colorectal, prostate, and stomach cancers, contributing significantly to the global oncological landscape. Stomach cancer emerges as the most common infection-related cancer on a worldwide scale, followed closely by liver and cervical infections, which underlines the intricate connection between infections and certain types of cancer. The impact of cancer on mortality is profound, causing about 1 in every six deaths worldwide and securing its position as the second leading cause of death globally, trailing only cardiovascular diseases. 

The geographical distribution of common cancers worldwide presents variations in the prevalence of different types of cancer across countries. Establishing a sustainable infrastructure for disseminating cancer prevention measures is deemed crucial in addressing this complex global health challenge. Notably, the burden of cancer is on the rise in almost every country, with approximately 40% of cancer cases believed to be preventable by addressing risk factors related to diet, nutrition, and physical activity. 

The World Cancer Research Fund’s estimated 18,094,716 million diagnosed cases in the same year provides a comprehensive perspective. When considering all cancers (excluding non-melanoma skin cancer) and aggregating data for both men and women, the age-standardized rate was 190 cases per 100,000 individuals. Notably, this rate was higher among men, with 206.9 cases per 100,000, compared to women, who had a rate of 178.1 cases per 100,000 individuals. These figures underscore the nuanced impact of cancer, necessitating a holistic approach to understanding and addressing this global health challenge. 

In 2023, the American Cancer Society (ACS) projected approximately 1.9 million new cancer cases in the United States. This estimate excludes basal and squamous cell skin cancers, which are not mandated for registry reporting. Similarly, carcinoma in situ (excluding urinary bladder cancer) is not included. The anticipated death toll from cancer in the U.S. for the same year is estimated at 609,820, equivalent to 1670 deaths per day.

The global cancer market is experiencing rapid growth. This expansive market covers prevention, diagnosis, and treatment, segmented by various factors. Notable cancer types in North America contribute to regional dominance, while the Asia-Pacific region is poised for the highest growth. Valued at USD 305.07 billion in 2022, the market is predicted to reach USD 556.35 billion by 2030, fueled by rising global cancer cases and technological advancements.

The pricing of cancer therapies, particularly biologics, is a crucial aspect influenced by market forces and comparative effectiveness research, with ongoing challenges in global price comparisons and a need for valid data in resource allocation. Bristol-Myers Squibb Company (NYSE:BMY) and AstraZeneca PLC (NASDAQ:AZN) are key players making substantial contributions to cancer treatment, emphasizing personalized medicine and innovative research.

Bristol-Myers Squibb Company (NYSE:BMY)’s recent advancement in non-small cell lung cancer treatment highlights its commitment, while AstraZeneca PLC (NASDAQ:AZN) focuses on redefining cancer care, conducting clinical trials, and aiming to contribute to breast cancer elimination. Both Bristol-Myers Squibb Company (NYSE:BMY) and AstraZeneca PLC (NASDAQ:AZN) are actively shaping the future of cancer treatment with significant investments and ambitious goals. 

A scientist in a laboratory, working on developing a new cancer therapy.

Our Methodology  

For our methodology, we have ranked the deadliest and most common cancers in the world based on the total estimated deaths caused by each of these cancers in 2023. For the data accuracy, we relied on SEER

Here is our list of the 17 deadliest and most common cancers in the world.  

17. Stomach Cancer

Estimated Deaths: 11,130

Stomach cancer, or gastric cancer, is a major global health issue, causing around 11,130 deaths in 2023. With 1.1 million new cases diagnosed, it represents 5.6% of all cancer cases. The five-year survival rate is less than 20%. The financial burden is substantial, with one study showing a one-year out-of-pocket expenditure of $5,368 for a newly diagnosed patient in China, and an average expenditure of $9,899 per patient, mainly on medical costs.

16. Oral Cavity And Pharynx Cancer

Estimated Deaths: 11,580

Oral cavity and pharynx cancer is one of the deadliest and most common cancers in the world, with an estimated 11,580 deaths in 2023. Incidence rates are higher in males, with the highest mortality rates among those aged 65–74. Mortality rates are increasing, particularly for oropharyngeal cancer. Tobacco use, alcohol consumption, and HPV infection are significant risk factors.  Ongoing research aims to enhance early detection methods, develop targeted therapies, and understand HPV’s role in cancer development.

15. Myeloma 

Estimated Deaths: 12,590 

Multiple myeloma, a blood cancer affecting plasma cells in the bone marrow, is among the deadliest and most prevalent cancers globally. It can lead to complications such as bone pain, anemia, kidney issues, and a weakened immune system. While considered incurable, treatments like chemotherapy, immunomodulatory drugs, and stem cell transplants aim to manage the disease and enhance the patient’s quality of life. Ongoing research promises future advancements, including studies on combination therapies and novel immunotherapy approaches. Although relatively uncommon in the U.S. (1 in 132 lifetime risk), an estimated 35,730 new cases are anticipated in 2023, as per the American Cancer Society

14. Uterine Cancer 

Estimated Deaths: 13,030 

Uterine cancer, or endometrial cancer, primarily affects post-menopausal women, with the majority of cases in those aged 55-64. It is the sixth leading cause of cancer death in the U.S., with 97,370 worldwide deaths in 2020. Mortality rates, especially among Black women, are increasing. The 5-year survival rate is 81%, higher for White women (84%) than Black women (64%). Uterine cancer can be lethal, often diagnosed at advanced stages, linked to hormonal imbalance, obesity, diabetes, and family history. Treatment involves surgery, radiation, and chemotherapy, with ongoing research exploring immunotherapy and targeted therapy. Endometrial cancers (95% of cases) and uterine sarcomas constitute the two primary types. Approximately 66,200 new cases are estimated in the U.S. in 2023. 

13. Ovarian Cancer 

Estimated Deaths: 13,270 

Ovarian cancer is a common and deadly cancer, often diagnosed at an advanced stage. Surgery and chemotherapy are the main treatments, with success depending on factors like cancer type and grade. Early detection improves outcomes, but the lack of symptoms leads to late diagnoses in 6 out of 10 cases. Recent advancements include FDA-approved drugs for advanced cases, ongoing clinical trials for new treatments, and studies on auranofin, sirolimus, olaparib, and pembrolizumab. Ovarian cancer has three main types: epithelial (90%), germ cell (4%), and stromal. It ranks fifth in cancer deaths among women, with a 1 in 78 lifetime risk. 

12. Kidney Cancer 

Estimated Deaths: 14,890 

Kidney cancer, one of the deadliest and most common cancers in the world, sees around 14,890 deaths annually. The average age of diagnosis is 64, with a higher incidence in men and certain ethnic groups. Survival rates vary by cancer stage, with 5-year survival ranging from 93% for localized cancer to 72% for regional spread. Mortality rates have declined slightly since the mid-1990s but have increased in the UK. Detection often occurs incidentally through imaging tests. Ongoing research aims to improve early detection and develop new treatments by understanding genetic and molecular factors driving the disease. 

11. Esophageal Cancer 

Estimated Deaths: 16,120 

Esophageal cancer, a leading cause of cancer-related deaths worldwide, affects the tube connecting the throat to the stomach. Symptoms include difficulty swallowing, weight loss, and pain. Treatment options include surgery, chemotherapy, radiation therapy, and immunotherapy, with ongoing clinical trials exploring new approaches. Immunotherapy has shown promising results in improving survival rates and quality of life. Additionally, research is investigating the use of aspirin and acid-reducing medication to prevent esophageal adenocarcinoma in individuals with Barrett’s esophagus. Men are more commonly affected than women, with a higher lifetime risk observed in males. 

10. Bladder Cancer 

Estimated Deaths: 16,710 

Bladder cancer stands among the deadliest cancers in the world, primarily affecting older individuals. Radical cystectomy, while curative, poses high risks, especially for older patients. Recent immunotherapy and targeted therapy advancements offer promising, less toxic treatment options. Clinical trials explore combining pembrolizumab with chemotherapy and radiation to preserve the bladder in localized cases. Research investigates drugs like gemcitabine and pembrolizumab to inhibit tumor growth and enhance immune response. Urothelial carcinoma is the most common type of bladder cancer, with decreasing death rates but an estimated 16,710 deaths in the US in 2023. 

9. Brain and Spine Cancer 

Estimated Deaths: 16,710 

Brain and spine cancer also stand among the deadliest cancers worldwide. Survival rates vary by age, with a 5-year relative survival rate of 75% for those under 15, 72% for ages 15-39, and 21% for ages 40 and older. Treatment typically involves surgery, radiation, and chemotherapy, but cure depends on factors like cancer type and stage. Studies indicate that brain and spinal cord tumors rank among the most frequent malignancies globally. In 2023, an estimated 24,810 adults in the US were diagnosed with primary tumors of the brain and spinal cord. 

8. Non-Hodgkin Lymphoma 

Estimated Deaths: 20,180 

Non-Hodgkin lymphoma (NHL) is a prevalent and deadly cancer worldwide, with around 80,620 new cases and 20,140 deaths expected in the US in 2024. Survival rates vary by age and have improved over the years, with a 5-year relative survival rate of approximately 72% in the US and over 80% for those aged 15-44 in England. The financial burden of the NHL can be substantial, with around 3% of cases in the UK considered preventable. 

7. Leukemia 

Estimated Deaths: 23,710 

Leukemia stands seventh among the deadliest and most common cancers in the world and accounts for a significant portion of cancer deaths worldwide. With an estimated 59,610 new cases and 23,710 deaths in the US in 2023, it ranks as one of the leading causes of cancer death. Financially, treating leukemia incurs substantial costs, totaling $89,000 for chronic leukemia per person and more than $460,000 for acute leukemia. Research has advanced understanding and treatment, leading to targeted therapies and identification of genetic biomarkers, but ongoing efforts focus on developing more effective treatments and overcoming drug resistance. 

6. Bile Duct Cancer 

Estimated Deaths: 29,380 

Bile duct cancer, or cholangiocarcinoma, is rare and aggressive, with poor survival rates varying by stage. Surgical resection offers a chance for cure, but long-term follow-up is needed. The financial burden can be substantial, including surgery and chemotherapy costs. Studies focus on improving understanding and treatment outcomes. It affects around 8,000 people annually in the US, with diagnoses often occurring at advanced stages. Palliative care is standard for symptom management. 

Click to see and continue reading the 5 Deadliest And Most Common Cancers In The World.

Suggested Articles:

Disclosure. None: The 17 Deadliest And Most Common Cancers In The world is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!